News

Endocrine Disruptors Cause Range of Diseases; E157 Billion Cost

Exposure to endocrine-disrupting chemicals results in a range of human diseases and abnormalities, costing a total of roughly E157 billion (about $175 billion) annually in the European Union, a new analysis shows.

Miriam E Tucker, Medscape, Mar 6, 2015

The findings were presented March 5 at a press briefing here at the Endocrine Society's annual meeting, ENDO 2015, and were also published online in a series of four articles in the Journal of Clinical Endocrinology and Metabolism.

With exposures occurring via pharmaceuticals, industrial solvents, personal-care products, aluminum-can linings, plasticizers, pesticides, and environmental pollutants, chemicals known to be endocrine disrupting include diethylstilbestrol, polychlorinated biphenyls (PCBs) , dioxins, perfluoroalkyl compounds, solvents, phthalates, bisphenol A (BPA), dichlorodiphenyldichloroethylene organophosphate/organochlorine pesticides, and polybrominated diphenyl.

Affected hormones include estrogen, androgen, thyroid, retinol, aryl hydrocarbon, and the peroxisome proliferator-activated receptor (PPAR) pathway. In all, 13 chronic conditions have strong scientific evidence for causation by endocrine-disrupting chemicals, Dr Trasande said.

Although this is a complex global, environmental public-health issue, on a clinical level physicians can counsel patients about avoiding these exposures, he told Medscape Medical News.

"There are safe and simple steps that families can take to limit their exposure to endocrine-disruptive chemicals. They can avoid microwaving plastic. They can avoid eating from aluminum cans or drinking fluids from aluminum cans. They can eat organic. Or even simply air out their homes every couple of days to remove some of the chemical dust…that can disrupt hormones in their bodies."

He added, "I recognize that doctors have extremely busy practices and many competing priorities. But in the context of the substantial burden of disease that we've identified and for which endocrine-disrupting chemicals are responsible and the opportunities for prevention that are much easier than perhaps intervening on diet and physical activity, there can be substantial impact."

Briefing moderator R Thomas Zoeller, PhD, from the University of Massachusetts, Amherst, and a coauthor of the paper on the costs of endocrine-disrupting chemical-associated neurobehavioral deficits and diseases, agreed. "In the conversation about diet and exercise, it should come up. I think it's beginning to be, and it's even mentioned in clinical textbooks right now."

The European Food Safety Authority (EFSA has recently ruled, however, that at least one such chemical, BPA - used to stiffen some plastic food containers - poses no health risk to consumers of any age, including unborn children, at current levels of exposure. The Food and Drug Administration banned BPA from baby bottles in 2012 but said there was not enough evidence for a wider ban and has found the chemical safe at low levels. The EFSA acknowledged in its assessment in January that BPA residues could migrate into foods and drinks and be ingested by consumers or be inhaled or absorbed, but exposure of this kind was "considerably under" the safe level known as the "tolerable daily intake," it said.

High Cost of Endocrine Disruption

The new analysis reported at ENDO 2015 is a response to an EU call for an impact assessment of laws enacted in 2009 and 2011 mandating limits on endocrine-disrupting pesticides and biocides.

Using estimates based on the literature and established statistical methods adapted from those used by the Intergovernmental Panel on Climate Change, Dr Trasande led a 12-member scientific steering committee, which determined that there was probable causation of endocrine-disrupting chemicals for IQ loss and associated intellectual disability, autism, attention-deficit/hyperactivity disorder (ADHD), childhood obesity, adult obesity, adult diabetes, cryptorchidism, male infertility, and mortality associated with reduced testosterone.

Using mid-point estimates for probability of causation, the panel calculated a median cost of €157 billion, or 1.23% of the EU gross domestic product, with a lower median range of €119 billion and a high end estimate of €270 billion.

Dr Trasande summarized results from the four papers at the briefing, including these data points:

Dr Trasande said that a similar analysis for the United States would be "the logical next step" and that he would anticipate analogous findings, although there are some differences. Brominated flame retardants are more stringently limited in Europe, for example, but levels of phthalates have decreased 17% to 37% in the United States between 2001 and 2010.

"Silent Epidemic Taking Away Human Potential"

In response to a reporter's somewhat skeptical question about whether this is a "real problem," Dr Trasande acknowledged that this is in many ways a "silent epidemic" that isn't manifested in any obvious way, but rather in subtle shifts in public health.

Nonetheless, he said, "It's a real epidemic supported by a substantial mountain of human and laboratory evidence suggesting that endocrine-disrupting chemicals [disturb] a broad array of hormonal processes [necessary] for human health."

According to Dr Zoeller, "There's a concept that if there isn't overt toxicity then you don't really have a problem. With endocrine disruption, we see effects on the population level that aren't consistent with overt toxicity like death or in some cases cancer.

"But think about a decrease in IQ levels. It's not visible on the surface, but you're taking away human potential.…It's very well-documented that PCBs and other chemicals have this effect. I think we need to begin to think in a little more sophisticated way than there's either normality or abnormality that's visible on the face of your children."

The studies were supported by the Endocrine Society, the John Merck Fund, the Broad Reach Foundation, and the Oak Foundation. Dr Trasande and Dr Zoeller report no relevant financial relationships. Disclosures for the coauthors are listed in the articles.

ENDO 2015: The Endocrine Society 97th Annual Meeting. Abstract S65-2, presented March 7, 2015.

Return to Home

Switch to full site >>

sales@dealookup.com
Copyright © 2024 DEA Lookup.com, Inc. All rights reserved.